Novel aldose reductase inhibitors: A patent survey (2006 present)

dc.contributor.author	Chatzopoulou, M	en
dc.contributor.author	Alexiou, P	en
dc.contributor.author	Kotsampasakou, E	en
dc.contributor.author	Demopoulos, VJ	en
dc.date.accessioned	2014-06-06T06:51:56Z
dc.date.available	2014-06-06T06:51:56Z
dc.date.issued	2012	en
dc.identifier.issn	13543776	en
dc.identifier.uri	http://dx.doi.org/10.1517/13543776.2012.726615	en
dc.identifier.uri	http://62.217.125.90/xmlui/handle/123456789/5779
dc.subject	Aldose reductase (ALR2)	en
dc.subject	Aldose reductase inhibitors (ARIs)	en
dc.subject	Cancer	en
dc.subject	Inflammation	en
dc.subject	Long-term diabetic complications	en
dc.subject.other	acetic acid derivative	en
dc.subject.other	aldehyde reductase	en
dc.subject.other	aldose reductase inhibitor	en
dc.subject.other	birch extract	en
dc.subject.other	caffeic acid derivative	en
dc.subject.other	chamomile	en
dc.subject.other	cryptomeria japonica extract	en
dc.subject.other	dimorphandra mollis extract	en
dc.subject.other	epalrestat	en
dc.subject.other	Erythroxylum catuaba extract	en
dc.subject.other	Euphrasia extract	en
dc.subject.other	Fagus crenata extract	en
dc.subject.other	Fargus crenata extract	en
dc.subject.other	fidarestat	en
dc.subject.other	Fomitopsis pinicola extract	en
dc.subject.other	Larches extract	en
dc.subject.other	Larix gmelinii extract	en
dc.subject.other	Nelumbo nucifera extract	en
dc.subject.other	onion extract	en
dc.subject.other	peanut extract	en
dc.subject.other	plant extract	en
dc.subject.other	plum tree extract	en
dc.subject.other	Pterocarya rhoifolia extract	en
dc.subject.other	Pterrcarya rhoifolia	en
dc.subject.other	Quercus acutissima extract	en
dc.subject.other	Quercus extract	en
dc.subject.other	quinic acid	en
dc.subject.other	ranirestat	en
dc.subject.other	sawtooth oak tree extract	en
dc.subject.other	unclassified drug	en
dc.subject.other	unindexed drug	en
dc.subject.other	asthma	en
dc.subject.other	cancer inhibition	en
dc.subject.other	crystal	en
dc.subject.other	diabetes mellitus	en
dc.subject.other	diabetic neuropathy	en
dc.subject.other	drug formulation	en
dc.subject.other	drug mechanism	en
dc.subject.other	drug structure	en
dc.subject.other	drug targeting	en
dc.subject.other	enzyme inhibition	en
dc.subject.other	enzyme localization	en
dc.subject.other	enzyme structure	en
dc.subject.other	glucose metabolism	en
dc.subject.other	human	en
dc.subject.other	inflammatory disease	en
dc.subject.other	neoplasm	en
dc.subject.other	nonhuman	en
dc.subject.other	patent	en
dc.subject.other	pathology	en
dc.subject.other	physical chemistry	en
dc.subject.other	protein domain	en
dc.subject.other	review	en
dc.subject.other	sepsis	en
dc.subject.other	Aldehyde Reductase	en
dc.subject.other	Animals	en
dc.subject.other	Anti-Inflammatory Agents	en
dc.subject.other	Antineoplastic Agents	en
dc.subject.other	Drug Design	en
dc.subject.other	Enzyme Inhibitors	en
dc.subject.other	Humans	en
dc.subject.other	Hypoglycemic Agents	en
dc.subject.other	Molecular Structure	en
dc.subject.other	Patents as Topic	en
dc.subject.other	Protein Conformation	en
dc.subject.other	Structure-Activity Relationship	en
dc.title	Novel aldose reductase inhibitors: A patent survey (2006 present)	en
heal.type	other	en
heal.identifier.primary	10.1517/13543776.2012.726615	en
heal.publicationDate	2012	en
heal.abstract	Introduction: Initially studied for its central role in the pathogenesis of chronic diabetic complications, aldose reductase (ALR2) gains more attention over the years as its implication in inflammatory diseases is being established, along with the therapeutic potential of its inhibitors. Areas covered: Reviewing the patents that were published since 2006, it is getting clear that the search for new chemical entities has subsided, giving rise to natural products and plant extracts with ALR2 inhibitory activity. Other aspects that were prominent were the search for proper forms of known inhibitors, in a way to improve their impaired physicochemical profile, as well as potential combination therapies with other compounds of pharmaceutical interest. On the spotlight were patents enhancing the therapeutic usage of aldose reductase inhibitors (ARIs) to various pathological conditions including cancer and inflammation-mediated diseases such as sepsis, asthma, and cancer. Expert opinion: Although new chemical entities are scarcely registered and patented after many years of inconclusive clinical trials, the involvement of ALR2 to inflammatory pathologies might renew the interest in the field of ARIs. © 2012 Informa UK, Ltd.	en
heal.journalName	Expert Opinion on Therapeutic Patents	en
dc.identifier.issue	11	en
dc.identifier.volume	22	en
dc.identifier.doi	10.1517/13543776.2012.726615	en
dc.identifier.spage	1303	en
dc.identifier.epage	1323	en